CeNeS stock soars as UK firm mulls over possible sale
Shares in CeNeS Pharmaceuticals have leapt almost 65% on the news that it is in talks that may lead to a sale of the UK company.
Read MoreAuthor: Kevin Grogan
GSK and SkyePharma hit by fresh delay to Requip XL in USA
Regulators in the USA have again delayed a decision on approval of an extended-release version of GlaxoSmithKline’s Parkinson’s disease drug Requip.
Read MoreForest excited over extended-release Alzheimer drug data
Forest Laboratories has been boosted by positive data from a late-stage trial of a once-daily version of its Alzheimer’s disease drug Namenda.
Read MoreAstraZeneca excited by potential of emerging markets
Like many drug majors, AstraZeneca is looking for further growth in China but there are other emerging markets that are also performing very well for the Anglo-Swedish drugmaker.
Read MoreAstraZeneca puts its faith in Crestor and biologics
After presenting a reasonable set of financials, and amid fears of generic competition to Nexium and Seroquel, AstraZeneca has been speaking at its results in London about the future and its bid to strengthen the pipeline.
Read More
